Phase I and pharmacokinetic study of flavopiridol followed by 1-β-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

Clinical Cancer Research

Volumn 11, Issue 23, 2005, Pages 8403-8412

  Karp, Judith E ^a,b   Passaniti, Antonino ^b   Gojo, Ivana ^b   Kaufmann, Scott ^d   Bible, Keith ^d   Garimella, Tushar S ^b   Greer, Jacqueline ^a,b   Briel, Janet ^a   Smith, B Douglas ^a   Gore, Steven D ^a   Tidwell, Michael L ^b   Ross, Douglas D ^b,c   Wright, John J ^e   Colevas, A Dimitrios ^e   Bauer, Kenneth S ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; ALUMINUM HYDROXIDE; ANTIEMETIC AGENT; CORTICOSTEROID; CYCLIN DEPENDENT KINASE; CYTARABINE; FAMCICLOVIR; FLAVOPIRIDOL; MITOXANTRONE; NORFLOXACIN; OCTREOTIDE; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; BONE MARROW SUPPRESSION; CANCER RELAPSE; CANCER RESISTANCE; CARDIOTOXICITY; CELL COUNT; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG ELIMINATION; DRUG INFUSION; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; GASTROINTESTINAL MOTILITY; HEART ARRHYTHMIA; HERPES SIMPLEX VIRUS; HORMONAL THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; INFLAMMATION; MALE; MAXIMUM TOLERATED DOSE; MENSTRUATION; MUCOSA INFLAMMATION; MYCOSIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RNA TRANSLATION; SIDE EFFECT; SUDDEN DEATH; TUMOR CELL DESTRUCTION; VIRUS ACTIVATION; VOMITING;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW CELLS; CATTLE; CELL PROLIFERATION; COHORT STUDIES; CYTARABINE; ENDOTHELIUM, VASCULAR; FEMALE; FLAVONOIDS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOXANTRONE; NEOPLASM RECURRENCE, LOCAL; PIPERIDINES; SALVAGE THERAPY; U937 CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 28544443503     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1201     Document Type: Article

References (50)

1. Maik RG, Kattice S, Bhat SV, Alreja B, de Souza NJ, Rupp RH. An antiinflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron 1998;44:2081-6.
2. Senderowicz AM, Sausville EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376-87.
3. Bible KC, Kaufmann SH. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 1996;56: 4856-61.
4. Decker RH, Dai Y, Grant S. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ 2001;8:715-24.
5. Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res 2002; 8:3527-38.
6. Yu C, Rahmani M, Dai Y, et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependem pathway. Cancer Res 2003;63:1822-33.
7. 1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK 4 in human breast carcinoma cells. Cancer Res 1996;56: 2973-8.
8. cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Biochem Pharmacol 1993; 46:1831-40.
9. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276:31793-9.
10. Lam LT, Pickeral OK, Peng AC, et al. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001;2:1-11.
11. Carlson B, Lahusen T, Loaiza-Perez A, et al. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999;59:4634-43.
12. Craig RW. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002;16:444-54.
13. Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005;307:1101-4.
14. Kaufmann SH, Karp JE, Svingen PA, et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998;91:991-1000.
15. Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood 2000; 96:393-7.
16. Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004;64:3517-24.
17. Mellilo G, Sausville EA, Cloud K, Lahusen T, Varresio L, Senderowicz A. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999;59:5433-7.
18. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
19. Buchner T, Hiddeman W, Wormann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93:4116-24.
20. Feldman EJ, Alberts DS, Arlin Z, et al. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol 1993;11: 2002-9.
21. Weiss M, Maslak P, Feldman E, et al. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996;14:2480-5.
22. Datta R, Banach D, Kojima H, et al. Activation of the CPP32 protease in apoptosis induced by 1-β-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 1996;88:1936-43.
23. Ho AD, Seither E, Ma DDF, et al. Mitoxantrone-induced toxicity and DNA strand breaks in leukemic cells. Br J Haematol 1987;65:51-5.
24. Bhalla K, Ibrado AM, Tourkina E, et al. High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1993; 82:3133-40.
25. Rowe TC, Chen GL, Hsiang YH, Liu LF. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II. Cancer Res 1986;46:2021-6.
26. Bible KC, Kaufmann SH. Cytotoxic synergy between Flavopiridol (NSC 649890, L86-8278275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res 1997;57: 3375-80.
27. Karp JE, Ross DD, Yang W, et al. Timed sequential therapy of acute leukemia with flavopiridol: In vitro model for a phase I clinical trial. Clin Cancer Res 2003;9:307-15.
28. Burke PJ, Karp JE, Braine HG, Vaughan WP. Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors. Cancer Res 1997;37:2138-46.
29. Karp JE, Donehower RC, Enterline J, Dole GB, Fox MG, Burke RJ. In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood 1989;73:24-30.
30. Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995;13:11-8.
31. Geller RB, Burke PJ, Karp JE, et al. S. A two-step timed sequential treatment for acute myelocytic leukemia. Blood 1989;p74:1499-506.
32. Woods WG, Alonzo TA, Lange BJ, Jena S, Estey EH. Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): comparison of outcomes between patients treated on childhood or adult protocols. Blood 2001;98:462a.
33. Tan AR, Headlee D, Messman R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20:4074-82.
34. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Acute Leukemia Group B study 19805. Clin Cancer Res 2005;11: 4176-81.
35. Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986;70: 1059-65.
36. Karp JE, Gojo I, Pili R, et al. Targeting vascular endothelial growth factor (VEGF) for relapsed and refractory adult acute myelogenous leukemias (AMLs): therapy with sequential ara-C, mitoxantrone and bevacizumab. Clin Cancer Res 2004;10:3577-85.
37. Kahn ME, Senderowicz A, Sausville EA, Barrett KE. Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol. Clin Cancer Res 2001;7: 343-9.
38. Rudek MA, Bauer KS, Jr., Lush RM III, et al. Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Ann Pharmacother 2003;37: 1369-74.
39. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9.
40. Bible KC, Bible RH, Kottke TJ, et al. Flavopiridol binds to duplex DNA. Cancer Res 2000;60:2419-28.
41. Zhang B, Gojo I, Fenton RG. MCL-1 is a critical survival factor for multiple myeloma. Blood 2002;99: 1885-93.
42. Nakanishi T, Karp JE, Tan M, et al. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin Cancer Res 2003;9:3320-8.
43. Byrd JC, Lin T, Dalton J, et al. Flavopiridol administered as a pharmacologically derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia. Blood 2004; 104:101a.
44. Le Gouill S, Podar K, Amiot M, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004;104:2886-92.
45. Litz J, Carlson P, Warshamana-Greene GS, Grant S, Krystal GW. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clin Cancer Res 2003;9:4586-94.
46. Ma Y, Cress WD, Haura EB. Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol Cancer Ther 2003;2: 73-81.
47. Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
48. Yu C, Krystal G, Dent P, Grant S. Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin Cancer Res 2002;8:2976-84.
49. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002;16:1331-43.
50. Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia 2004;18:1780-8.